CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
601-615 of 1225
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
MinuteCE®Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Sapna Patel, MD
John M. Kirkwood, MD
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
John M. Kirkwood, MD
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Sapna Patel, MD
- advertisement
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
MinuteCE®Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Paolo A. Ascierto, MD
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Hussein Tawbi, MD, PhD
Paolo A. Ascierto, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CEAddressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Amy Mottl, MD, MPH
Muthiah Vaduganathan, MD, MPH
- advertisement
ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
CME/CEADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
Reshma L. Mahtani, DO
Managing Adverse Events Associated With Menin Inhibitors
MinuteCE®Managing Adverse Events Associated With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
Emerging Directions in Menin-Directed AML Therapy
MinuteCE®Emerging Directions in Menin-Directed AML Therapy
Ghayas Issa, MD
Amir Fathi, MD